Funding news · Sep 2, 2026
Sensible Biotechnologies Raises $13.5M Series A for Cell-Based mRNA Manufacturing Platform
Sensible Biotechnologies Raises $13.5M Series A
Sensible Biotechnologies has raised a $13.5 million Series A round, according to funding data dated September 2, 2026. The round was raised in USD.
What the Company Does
Sensible Biotechnologies is developing the first cell-based platform for the design, optimisation and manufacturing of mRNA therapeutics. Rather than relying on enzyme-heavy in vitro transcription, the company engineers host cells to produce long, pure, low-immunogenicity transcripts.
The platform pairs its biology with an AI-guided sequence-design suite built on NVIDIA accelerated computing.
Company Background
- Founded in 2021
- Part of Y Combinator's Summer 2021 batch
- Operates from Boston, Oxford and Bratislava
- Backers include BlueYard Capital, Recode Ventures, Kaya VC, Backed VC, Y Combinator, ZAKA VC and Onsight
Round Details
| Field | Detail |
|---|---|
| Round type | Series A |
| Amount | $13,500,000 |
| Currency | USD |
| Date | September 2, 2026 |
No lead investor was disclosed in the funding data, and no investor list was provided for this round.
Why It Matters
mRNA therapeutics manufacturing has traditionally depended on in vitro transcription, an enzyme-intensive process. Sensible Biotechnologies' approach moves production into engineered host cells, aiming to generate longer, purer transcripts with lower immunogenicity. Combined with AI-guided sequence design, the company is positioning itself across both the design and manufacturing layers of mRNA development.
With operations spanning Boston, Oxford and Bratislava, Sensible Biotechnologies maintains a transatlantic footprint that supports both its biology platform and its computational design work.
Acquisition Angle
The Series A gives Sensible Biotechnologies additional capital to advance a platform that sits at the intersection of synthetic biology, mRNA therapeutics and AI-driven design. For acquirers in biotech tools, mRNA manufacturing or computational biology, the company offers a differentiated cell-based production route plus an NVIDIA-accelerated sequence-design suite. Its existing investor base — including BlueYard Capital, Recode Ventures, Kaya VC, Backed VC, Y Combinator, ZAKA VC and Onsight — provides a syndicate familiar with early-stage platform companies.
Summary
- Company: Sensible Biotechnologies
- Round: Series A
- Amount: $13.5 million USD
- Date: September 2, 2026
- Focus: Cell-based mRNA design, optimisation and manufacturing, plus AI-guided sequence design
- Founded: 2021, Y Combinator Summer 2021 batch
- Locations: Boston, Oxford, Bratislava